Literature DB >> 33397173

COQ2 mutation associated isolated nephropathy in two siblings from a Chinese pedigree.

Min Li1, Zhihui Yue2, Hongrong Lin1, Haiyan Wang3, Huamu Chen1, Liangzhong Sun1.   

Abstract

BACKGROUD: Coenzyme Q10 (CoQ10) is involved in the biosynthesis of adenosine triphosphate (ATP), and is most abundant in the mitochondrial membrane. The primary CoQ10 deficiency caused by COQ2 defect is mostly manifested as encephalopathy, encephalopathy with nephropathy, and rarely as an isolated nephrotic syndrome.
METHODS: Clinical and pathological data and peripheral blood samples of 2 siblings with steroid-resistant nephrotic syndrome (SRNS) and their family members of a Chinese pedigree were collected. DNA was extracted and subjected to next-generation sequencing of target genes of hereditary nephropathy.
RESULTS: Compound heterozygous mutations of COQ2 (c.1058A > G, p.Y353C, paternal and c.973A > G, p.T325A, maternal)were identified in both siblings of the pedigree. Mutation of p.Y353C was novel. The proband was a girl, who presented with SRNS at the age of 7 months. CoQ10 was administered after the gene sequencing results came out. Proteinuria decreased gradually to 1+, occasionally negative. The child was normal in growth and intelligence. She is now 4 years old. The second patient was her elder brother. He was found to have SRNS at the age of 2 years old. Renal pathology indicated focal segmental glomerulosclerosis (FSGS). Electronic microcopy revealed that a large quantity of mitochondria with normal contour was accumulated within the podocytes. Both patients were in normal intelligence without convulsion.
CONCLUSION: The 2 cases harboring COQ2compound heterozygous mutations presented with isolated SRNS, with a renal pathology of FSGS and a large quantity of mitochondria with normal contour accumulated within the podocytes. CoQ10 was efficacy in eliminating proteinuria.

Entities:  

Keywords:  CoQ10; child; mitochondria; mutation; steroid-resistant nephrotic syndrome

Mesh:

Substances:

Year:  2021        PMID: 33397173      PMCID: PMC7801106          DOI: 10.1080/0886022X.2020.1864402

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  15 in total

Review 1.  [Clinical analysis of one infantile nephrotic syndrome caused by COQ2 gene mutation and literature review].

Authors:  K Xu; X Y Mao; Y Yao; H Cheng; X J Zhang
Journal:  Zhonghua Er Ke Za Zhi       Date:  2018-09-02

2.  The COQ2 genotype predicts the severity of coenzyme Q10 deficiency.

Authors:  Maria Andrea Desbats; Valeria Morbidoni; Micol Silic-Benussi; Mara Doimo; Vincenzo Ciminale; Matteo Cassina; Sabrina Sacconi; Michio Hirano; Giuseppe Basso; Fabien Pierrel; Placido Navas; Leonardo Salviati; Eva Trevisson
Journal:  Hum Mol Genet       Date:  2016-08-04       Impact factor: 6.150

Review 3.  Coenzyme Q biosynthesis and its role in the respiratory chain structure.

Authors:  María Alcázar-Fabra; Plácido Navas; Gloria Brea-Calvo
Journal:  Biochim Biophys Acta       Date:  2016-03-10

4.  A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency.

Authors:  Catarina Quinzii; Ali Naini; Leonardo Salviati; Eva Trevisson; Placido Navas; Salvatore Dimauro; Michio Hirano
Journal:  Am J Hum Genet       Date:  2005-12-22       Impact factor: 11.025

5.  Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency.

Authors:  Catarina M Quinzii; Luis C López; Robert W Gilkerson; Beatriz Dorado; Jorida Coku; Ali B Naini; Clotilde Lagier-Tourenne; Markus Schuelke; Leonardo Salviati; Rosalba Carrozzo; Filippo Santorelli; Shamima Rahman; Meriem Tazir; Michel Koenig; Salvatore DiMauro; Michio Hirano
Journal:  FASEB J       Date:  2010-05-21       Impact factor: 5.191

Review 6.  Clinical syndromes associated with Coenzyme Q10 deficiency.

Authors:  María Alcázar-Fabra; Eva Trevisson; Gloria Brea-Calvo
Journal:  Essays Biochem       Date:  2018-07-20       Impact factor: 8.000

7.  COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.

Authors:  Francesca Diomedi-Camassei; Silvia Di Giandomenico; Filippo M Santorelli; Gianluca Caridi; Fiorella Piemonte; Giovanni Montini; Gian Marco Ghiggeri; Luisa Murer; Laura Barisoni; Anna Pastore; Andrea Onetti Muda; Maria Luisa Valente; Enrico Bertini; Francesco Emma
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

8.  Response to Early Coenzyme Q10 Supplementation Is not Sustained in CoQ10 Deficiency Caused by CoQ2 Mutation.

Authors:  Fehime K Eroglu; Fatih Ozaltin; Nazlı Gönç; Hülya Nalçacıoğlu; Z Birsin Özçakar; Dilek Yalnızoğlu; Şafak Güçer; Diclehan Orhan; Fatma Tuba Eminoğlu; Rahşan Göçmen; Ayfer Alikaşifoğlu; Rezan Topaloğlu; Ali Düzova
Journal:  Pediatr Neurol       Date:  2018-07-27       Impact factor: 3.372

9.  ADCK3-related Coenzyme Q10 Deficiency: A Potentially Treatable Genetic Disease.

Authors:  Anna Chang; Marta Ruiz-Lopez; Elizabeth Slow; Mark Tarnopolsky; Anthony E Lang; Renato P Munhoz
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

10.  A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome.

Authors:  Carolin E Sadowski; Svjetlana Lovric; Shazia Ashraf; Werner L Pabst; Heon Yung Gee; Stefan Kohl; Susanne Engelmann; Virginia Vega-Warner; Humphrey Fang; Jan Halbritter; Michael J Somers; Weizhen Tan; Shirlee Shril; Inès Fessi; Richard P Lifton; Detlef Bockenhauer; Sherif El-Desoky; Jameela A Kari; Martin Zenker; Markus J Kemper; Dominik Mueller; Hanan M Fathy; Neveen A Soliman; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2014-10-27       Impact factor: 10.121

View more
  2 in total

1.  A novel COQ7 mutation causing primarily neuromuscular pathology and its treatment options.

Authors:  Ying Wang; Evren Gumus; Siegfried Hekimi
Journal:  Mol Genet Metab Rep       Date:  2022-05-05

2.  Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention.

Authors:  Xuyan Liu; Huasheng Du; Yan Sun; Leping Shao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.